Cardiovascular Regenerative Medicine
心血管再生医学
基本信息
- 批准号:8663728
- 负责人:
- 金额:$ 9.72万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-09-07 至 2016-04-30
- 项目状态:已结题
- 来源:
- 关键词:AgingAmputationAnimalsAutologousBeliefBiologyCD34 geneCardiovascular DiseasesCardiovascular systemCell SeparationCell TherapyCell physiologyCellsChest PainChronicClinical TrialsCollaborationsDataDefectDiabetes MellitusDiseaseDoctor of MedicineDoctor of PhilosophyEnvironmentEpigenetic ProcessExercise ToleranceFibrosisFunctional disorderGoalsHistologyHumanIndividualIschemiaKnowledgeLimb structureMethodsMitochondriaMyocardialOperative Surgical ProceduresOutcomePatientsPeptidesPlasminogen Activator Inhibitor 1Principal InvestigatorRecruitment ActivityRefractoryRegenerative MedicineRoleSafetyStem cellsTherapeuticTherapeutic Usesbasedesignimprovedinterestmembermolecular imagingnanomaterialsnovelphase 3 studyprogramsrepaired
项目摘要
DESCRIPTION (provided by applicant):
Recent data, generated as the result of a decade long effort by the Program PI to develop endothelial progenitor cell based therapeutics, provides evidence for the safety and efficacy of autologous progenitor cells for treatment of myocardial and limb ischemia. Specifically two recent human clinical trials have both yielded evidence that autologous human CD34+ cells improve outcome in patients with chronic, refractory ischemia: patients with intractable angina had significant reductions in chest pain and improved exercise tolerance, while patients with critical limb ischemia had reduced amputation rates. While we acknowledge that the final proof of progenitor cell based therapies in phase III studies is forthcoming, it is our belief that the available evidence for bioactivity and potential therapeutic utility of cell based therapy is substantial enough to justify efforts to augment their efficacy by exploiting our knowledge about their biology and further exploring mechanisms that may enhance their safety and therapeutic utility. The overarching goal of this PPG is to advance the therapeutic use of endothelial progenitor cells for the treatment of cardiovascular diseases. This objective will be achieved in the Program by four individual Projects that investigate certain mechanisms of progenitor cell fate, function and dysfunction, and explore novel, nanomaterial based methods to enhance their therapeutic application and by taking advantage of strategically designed Cores that will support each Project. Project 1: Enhancing Progenitor Cell Function using Bioactive Peptide Amphiphiles (Douglas W. Losordo, M.D. and Samuel Stupp Ph.D., Co-I) Project 2: Role of PAI-1 in Cardiovascular Repair and Fibrosis (Douglas E. Vaughan, M.D., PI) Project 3: Characterization of mitochondrial defects in EPCs in diabetes and aging (Hossein Ardehali, M.D., Ph.D., PI) Project 4: Epigenetic modulation of Endothelial Progenitor Cells for Cardiomyogenesis (Raj Kishore, Ph.D., PI) Core A: Small Animal Surgery and Histology (Tsutomu Kume, Ph.D., PI) Core B: Advanced Molecular Imaging (Tom Meade, Ph.D., PI) Core C: FACS Analysis and Cell Sorting (Harris Perlman, Ph.D., PI) Core D; Administrative Core (Douglas Losordo, M.D., PI)
PROJECT 1: Peptide Amphiphiles to Augment Progenitor Cell Therapies (Losordo, Douglas W.)
描述(由申请人提供):
最近的数据是PI计划十年来努力开发基于内皮祖细胞的疗法的结果,为自体祖细胞用于治疗心肌和肢体缺血的安全性和有效性提供了证据。具体地说,最近的两项人类临床试验都证明,自体人类CD34+细胞可以改善慢性难治性缺血患者的预后:顽固性心绞痛患者的胸痛显著减轻,运动耐量提高,而严重肢体缺血患者的截肢率降低。虽然我们承认在第三阶段研究中祖细胞疗法的最终证据即将到来,但我们相信基于细胞疗法的生物活性和潜在治疗效用的现有证据足够充分,足以证明通过利用我们对其生物学的知识和进一步探索可能增强其安全性和治疗效用的机制来增强其疗效的努力是合理的。该PPG的首要目标是促进内皮祖细胞在心血管疾病治疗中的治疗应用。该计划将通过四个单独的项目来实现这一目标,这些项目研究祖细胞命运、功能和功能障碍的某些机制,探索基于纳米材料的新方法,以增强其治疗应用,并利用将支持每个项目的战略性设计的核心。项目1:使用生物活性多肽两亲性增强祖细胞功能(Douglas W.Losordo,M.D.和Samuel Stupp Ph.D.,Co-I)项目2:PAI-1在心血管修复和纤维化中的作用(Douglas E.Vaughan,M.D.,Pi)项目3:糖尿病和老龄化中内皮祖细胞线粒体缺陷的特征(Hossein Ardehali,M.D.,Ph.D.,Pi)项目4:用于心肌发生的内皮祖细胞的表观遗传调节(Raj Kishore,Ph.D.,Pi)核心A:小动物手术和组织学(Tsutomu Kume,Ph.D.,Pi)。PI)核心B:高级分子成像(Tom Meade,Ph.D.,PI)核心C:FACS分析和细胞分类(Harris Perlman,Ph.D.,PI)核心D;管理核心(Douglas Losordo,M.D.,PI)
项目1:增加祖细胞疗法的两亲多肽(Losordo,Douglas W.)
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Douglas E Vaughan其他文献
1007-182 Aldosterone and plasma renin activity influence plasma plasminogen activato inhibitor-1 levels in overweight subjects
- DOI:
10.1016/s0735-1097(04)91875-x - 发表时间:
2004-03-03 - 期刊:
- 影响因子:
- 作者:
James A.S Muldowney;Barbara C Roberts;Joseph W Covington;John A Schoenhard;Nancy J Brown;Douglas E Vaughan - 通讯作者:
Douglas E Vaughan
1064-181 Distinct signaling pathways mediate protease activated receptor-dependent endothelial exocytosis
- DOI:
10.1016/s0735-1097(04)91968-7 - 发表时间:
2004-03-03 - 期刊:
- 影响因子:
- 作者:
John H Cleator;Douglas E Vaughan;Heidi E Hamm - 通讯作者:
Heidi E Hamm
Douglas E Vaughan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Douglas E Vaughan', 18)}}的其他基金
Evolutionary Advantage of Heterozygous PAI-1 Deficiency in Humans
人类杂合 PAI-1 缺陷的进化优势
- 批准号:
10686583 - 财政年份:2022
- 资助金额:
$ 9.72万 - 项目类别:
Spontaneous cardiac fibrosis in PAI-1-deficient mice and men: A rare mutation informs a common molecular pathophysiology
PAI-1 缺陷小鼠和男性的自发性心脏纤维化:一种罕见的突变揭示了一种常见的分子病理生理学
- 批准号:
10402774 - 财政年份:2019
- 资助金额:
$ 9.72万 - 项目类别:
Spontaneous cardiac fibrosis in PAI-1-deficient mice and men: A rare mutation informs a common molecular pathophysiology
PAI-1 缺陷小鼠和男性的自发性心脏纤维化:一种罕见的突变揭示了一种常见的分子病理生理学
- 批准号:
9908161 - 财政年份:2019
- 资助金额:
$ 9.72万 - 项目类别:
DEFINING STRATEGIES FOR IMPROVING ENDOTHELIAL/FIBRINOLYTIC DYFUNCTION IN OBESITY
制定改善肥胖症内皮/纤溶功能障碍的策略
- 批准号:
7605664 - 财政年份:2006
- 资助金额:
$ 9.72万 - 项目类别:
相似海外基金
Understanding the Heightened Amputation Risk Among People Experiencing Homelessness: A Population-based Cohort Study
了解无家可归者截肢风险升高:一项基于人群的队列研究
- 批准号:
480010 - 财政年份:2023
- 资助金额:
$ 9.72万 - 项目类别:
Operating Grants
Collaborative Research: An Integrated, Proactive, and Ubiquitous Prosthetic Care Robot for People with Lower Limb Amputation: Sensing, Device Designing, and Control
合作研究:针对下肢截肢患者的集成、主动、无处不在的假肢护理机器人:传感、设备设计和控制
- 批准号:
2246672 - 财政年份:2023
- 资助金额:
$ 9.72万 - 项目类别:
Standard Grant
Collaborative Research: An Integrated, Proactive, and Ubiquitous Prosthetic Care Robot for People with Lower Limb Amputation: Sensing, Device Designing, and Control
合作研究:针对下肢截肢患者的集成、主动、无处不在的假肢护理机器人:传感、设备设计和控制
- 批准号:
2246671 - 财政年份:2023
- 资助金额:
$ 9.72万 - 项目类别:
Standard Grant
Advancing measurement of physical function in upper limb amputation
推进上肢截肢身体功能的测量
- 批准号:
10749083 - 财政年份:2023
- 资助金额:
$ 9.72万 - 项目类别:
Collaborative Research: An Integrated, Proactive, and Ubiquitous Prosthetic Care Robot for People with Lower Limb Amputation: Sensing, Device Designing, and Control
合作研究:针对下肢截肢患者的集成、主动、无处不在的假肢护理机器人:传感、设备设计和控制
- 批准号:
2246673 - 财政年份:2023
- 资助金额:
$ 9.72万 - 项目类别:
Standard Grant
Establishing the Relationship Between Muscle Quality and Joint Loading for Individuals with Transtibial Amputation
建立小腿截肢患者的肌肉质量和关节负荷之间的关系
- 批准号:
10677236 - 财政年份:2023
- 资助金额:
$ 9.72万 - 项目类别:
Preventing Amputation through Management of Diabetic Foot; Working with Industry to generate supply chains in an LMIC setting (Uganda) for low-cost fo
通过糖尿病足管理预防截肢;
- 批准号:
2883969 - 财政年份:2023
- 资助金额:
$ 9.72万 - 项目类别:
Studentship
Diabetes Lower Extremity Complications Research and Training Network in Foot Ulcer and Amputation Prevention (DIALECT)
糖尿病下肢并发症足部溃疡和截肢预防研究与培训网络 (DIALECT)
- 批准号:
EP/X02699X/1 - 财政年份:2022
- 资助金额:
$ 9.72万 - 项目类别:
Research Grant
Myoelectric upper limb prosthesis with multiple degrees of freedom using targeted muscle reinnervation surgery for traumatic amputation
多自由度肌电上肢假肢,采用靶向肌肉神经支配手术治疗创伤性截肢
- 批准号:
22K16723 - 财政年份:2022
- 资助金额:
$ 9.72万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
An automatically-adjusting prosthetic socket for people with transtibial amputation
适用于小腿截肢患者的自动调节假肢接受腔
- 批准号:
10364108 - 财政年份:2022
- 资助金额:
$ 9.72万 - 项目类别: